Business · 30/11/2018Updated: 10/17/2026 · 1 min read
FDA Announces Public Meeting of Bone, Reproductive and Urologic Drugs Advisory Committee
Summary
The FDA is hosting a public meeting of its advisory committee to gather input on regulatory issues related to bone, reproductive, and urologic drugs, with a public comment period to follow.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →